Celadon Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 4/6
Celadon Pharmaceuticals has a total shareholder equity of £2.5M and total debt of £31.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are £8.5M and £6.0M respectively.
Informazioni chiave
1.3%
Rapporto debito/patrimonio netto
UK£31.00k
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | UK£16.00k |
| Patrimonio netto | UK£2.45m |
| Totale passività | UK£6.01m |
| Totale attività | UK£8.46m |
Aggiornamenti recenti sulla salute finanziaria
Nessun aggiornamento
Recent updates
Analisi della posizione finanziaria
Passività a breve termine: CEL's short term assets (£1.7M) exceed its short term liabilities (£878.0K).
Passività a lungo termine: CEL's short term assets (£1.7M) do not cover its long term liabilities (£5.1M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CEL's net debt to equity ratio (0.6%) is considered satisfactory.
Riduzione del debito: Insufficient data to determine if CEL's debt to equity ratio has reduced over the past 5 years.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: CEL has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Previsione Cash Runway: CEL is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.